WallStSmart

Vontier Corp (VNT)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vontier Corp generates 1088% more annual revenue ($3.08B vs $258.90M). VNT leads profitability with a 13.2% profit margin vs -15.5%. VNT earns a higher WallStSmart Score of 64/100 (C+).

VNT

Buy

64

out of 100

Grade: C+

Growth: 3.3Profit: 8.0Value: 8.7Quality: 5.3
Piotroski: 5/9Altman Z: 1.97

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VNTUndervalued (+59.7%)

Margin of Safety

+59.7%

Fair Value

$101.07

Current Price

$34.72

$66.35 discount

UndervaluedFair: $101.07Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VNT3 strengths · Avg: 8.7/10
Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

P/E RatioValuation
12.6x8/10

Attractively priced relative to earnings

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VNT3 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

EPS GrowthGrowth
4.3%4/10

4.3% earnings growth

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VNT

The strongest argument for VNT centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VNT

The primary concerns for VNT are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VNT profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SCIENTIFIC & TECHNICAL INSTRUMENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VNT scores higher overall (64/100 vs 41/100). ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vontier Corp

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Vontier Corporation is dedicated to the research and development, manufacture, sale and distribution of equipment, components, software and critical technical services for manufacturing, repair and service in the mobility infrastructure industry worldwide. The company is headquartered in Raleigh, North Carolina.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?